Skip to main content
. 2019 Jan 11;202(4):1200–1209. doi: 10.4049/jimmunol.1800998

FIGURE 4.

FIGURE 4.

BIVV009 prevents complement-enhanced proliferation of primary B cells. (A) Two representative flow cytometry plots of CD19+ B cell proliferation on day 8 after initial stimulation with CpG in mouse anti-human plate with activated complement deposited from the following sources: 5% NHS treated with 100 μg/ml human IgG4 (isotype), 5% NHS treated with 100 μg/ml BIVV009 (BIVV009), or 5% human C3dpl. Counting gates are shown. (B) Relative proliferation of CD19+CFSElow B cells normalized to an isotype control. Data shown are from independent experiments on B cells from 10 separate donors. (C) C3-split products ELISA of plates from (B). Statistics are one-way ANOVA. **p < 0.001.